BioSpace News Archive

Deals

Lilly Drops Nearly $1.93B for Versanis to Bolster Weight-Loss Portfolio

Eli Lilly said Friday it plans to pay up to $1.925 billion to acquire Versanis and its lead asset, bimagrumab, a monoclonal antibody that aims to reduce fat mass without affecting muscle mass.

July 14, 2023
·
2 min read
·
Rosemary Scott
Business

Week in Review: Licensing Deals, M&A, EU Regulators on a Tear, Latest in IRA Battle

This week: Cancer license deals from J&J and BeiGene, a potential $7B acquisition by Roche and confirmed $1.9B Lilly buy, EU fine for Illumina, and more legal challenges to the Inflation Reduction Act

July 14, 2023
·
2 min read
·
Greg Slabodkin
Policy

Opinion: Who Really Pays for Drug Development? Both Government and Industry

Bringing new drugs to the market costs billions of dollars. It could not be done without investments by both the NIH and biopharma companies.

July 14, 2023
·
5 min read
·
Fred D. Ledley
Drug Development

Caribou Scores Early CAR-T Lymphoma Win, Plans $125M Public Offering

In a Phase I trial, Caribou’s allogeneic CAR-T cell therapy candidate induced high rates of treatment response in patients with relapsed or refractory B cell non-Hodgkin lymphoma.

July 14, 2023
·
2 min read
·
Tristan Manalac
Policy

Regenerative Medicine Challenges Hinder Their Development and Use: GAO

A new report by the U.S. Government Accountability Office finds that despite the promise of regenerative medicine technologies they are held back by regulatory and manufacturing challenges.

July 14, 2023
·
4 min read
·
Tristan Manalac and Greg Slabodkin
Deals

Roche in Talks to Buy Stomach Drug from Roivant for $7B: Report

The Swiss pharma is in talks to acquire Roivant Sciences’ RVT-3101, an anti-TL1A antibody that recently showed promising results in a Phase IIb ulcerative colitis trial, reports The Wall Street Journal.

July 14, 2023
·
2 min read
·
Heather McKenzie
Business

Gilead Sciences to Release Second Quarter 2023 Financial Results on Thursday, August 3, 2023

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2023 financial results and guidance will be released on Thursday, August 3, 2023 after the market closes.

July 14, 2023
·
1 min read
Business

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2023 Financial Results

Cryo-Cell International, Inc., the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2023.

July 14, 2023
·
6 min read
Deals

Algernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory Agreement

Algernon Pharmaceuticals Inc. announces a non-brokered private placement for gross proceeds of CDN$205,000 (the “ Offering ”) of units (the “ Units ”) at an issue price of CDN$0.20 per Unit.

July 14, 2023
·
5 min read
RaySearch releases RayCare 2023B

RaySearch Laboratories AB announces the release of the latest version of RayCare®*, the next generation oncology information system.

July 14, 2023
·
2 min read